Kathleen C.M. Campbell, PhD
Kathleen Campbell, Ph.D., CCC-A, Distinguished Scholar and Research Professor at Southern Illinois University (SIU) School of Medicine, Department of Medical Microbiology, Immunology and Cell Biology was a clinician/clinic director in Canda and the United States for over 25 years buy has conducted full time research for the last 15 years. She is originally from South Dakota and obtained her Master's degree form the University of South Dakota and her PhD from the University of Iowa. She served on the American Academy of Audiology Board of Directors, received an American Academy of Audiology Presidential Citation for her work in developing professional practice standards jointly for the American Academy of Audiology, American Speech Language and Hearing Association and the Department of Veteran's Affairs. She also received two Medical Innovators Awards and is a fellow of the American Speech Language and Hearing Association. In 2011 she received Honors of the Association from the Illinois Academy of Audiology. She was the 2012 Inventor of the Year for the Southern Illinois University System. She was named SIU university-wide Distinguished Scholar for 2014, the university system's highest honor with one given per year. In 2016 she was awarded Honors of the Association from the American Speech Language, Hearing Association. In 2017 she received the Natalie Stukas Hearing Conservation Award. In 2019, she received an Honorary Doctor of Science Degree from A.T. Still University for her contributions to the profession of audiology.
She authored Essential Audiology for Physicians and edited/authored Pharmacology and Ototoxicity for Audiologists. She recently completed a Phase 3 clinical trial of D-methionine as an oral agent to prevent noise-induced hearing loss and tinnitus. These clinical trials are under an FDA IND and were funded by the US Department of Defense, US Army Research and Materiel Command, CDMRP. This clinical trial was featured on the front page of the Wall Street Journal. She has received over 60 grants from National Institutes of Health, US Department of Defense and other agencies for her research in otoprotective agents and is the sole inventor for the protective agent D-methionine patents. During her time at SIU she has secured over 11 million dollars in external funding. She has received 5 US and 33 foreign patents for her inventions for pharmacologic otoprotective agents.
Her research is focused on ototoxicity and otoprotective agents. She has served as principal investigator on more than 60 research grants, funded by agencies such as the Department of Defense, Veterans Administration, the Illinois Department of Public Health and the National Institutes of Health/National Institute of Aging and National Institute of Deafness and Communication Disorders.
General Laboratory Techniques:
Auditory Electrophysiologic Measures, Noise exposures, Spectrophotometry, Enzyme Analyses
2015-2020 R01 DC014549-01 NIDCD/NIH entitled “Optimizing D-methionine (D-met) Pre-loading and Rescue Dosing Through Functional and Biomarker Measures”. April 1, 2015 through March 31, 2020 $2,816,808.00 PI. Kathleen Campbell, PhD
“Therapeutic Use of D-Methionine to Reduce the Toxicity of Platinum-Containing Anti-Tumor Compounds” Inventor: Kathleen Campbell, U.S. Patent Application Serial No. 08/942,845, SIU File #7356. Issued February 13, 2001
“Therapeutic Use of D-methionine to Reduce the Toxicity of Ototoxic Drugs, Noise and Radiation” Inventor Kathleen C.M. Campbell, Patent No: 6,265,386 B1. Date of Patent July 24, 2001
“Therapeutic Use of D-Methionine to Reduce the Toxicity of Noise” Inventor: Kathleen C. M. Campbell, Patent No. 7,071,230 Date of Patent July 4, 2006
“ Therapeutic Use of Methionine-Derivatives to Reduce the Toxicity of Noise” U.S. Patent # 7,423,065 Application No. 11/324,744 issued September 9,2008
“Therapeutic Use of D-methionine to Reduce the Toxicity of Ototoxic Drugs, Noise, and Radiation” European Patent No. 98915362.2 Date of Patent June 25, 2003